NCT05017922已完成不适用
Efficacy of TACE Combined With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- Number of bleeding episodes
研究概览
简要总结
The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out predictors associated with survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCC was diagnosed in accordance with the 2017 edition of diagnosis guidelines, all patients were in CNLC stage Ib to IIIa, and treated with TACE;
- •EGV was demonstrated through endoscopic examination;
- •Child-Pugh grade A or B, or grade C patients improved liver function to grade A or B through aggressive treatment;
- •age between 18 and 75 years.
排除标准
- •HCC with diffuse or distant metastasis, or with other systemic malignancies;
- •severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome;
- •severe cardiac, cerebrovascular, lung and renal diseases and cannot tolerate endoscopic treatment;
- •severe coagulation dysfunction;
- •severe infection, bleeding with unstable vital signs;
- •history of liver surgery;
- •cannot or refuse to sign the informed consent.
结局指标
主要结局
Number of bleeding episodes
时间窗: In July 2020 or the day of death or the day of lost to follow-up or follow-up for 3 years
Differences of bleeding episodes between two groups
Time of overall survival
时间窗: In July 2020 or the day of death or the day of lost to follow-up or follow-up for 3 years
Differences of overall survival between two groups
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTTHepatocellular Carcinoma Non-resectableNCT04967495Second Affiliated Hospital of Guangzhou Medical University171
Unknown
4 期
TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT03996681Suzhou Municipal Hospital22
Unknown
不适用
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular CarcinomaHepatocellular CarcinomaNCT02529761Air Force Military Medical University, China330
已完成
2 期
TACE Combined With Sorafenib and Tislelizumab for Advanced HCCHepatocellular Carcinoma Non-resectableNCT04599777Second Affiliated Hospital of Guangzhou Medical University30
已完成
2 期
TACE Combined With Lenvatinib and Sintilimab for Advanced HCCHepatocellular Carcinoma Non-resectableNCT04599790Second Affiliated Hospital of Guangzhou Medical University30